Yihong YaoLead Immuno Oncology Clinical Development, Translational Medicine and Oncology R&D at Cellular Biomedicine Group, USA & China
Agenda Sessions
Promising Safety and Efficacy Profile of a Novel Anti-CD20/CD19 Bi-Specific CAR-T (C-CAR039) Cell Therapy in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
, 2:45pmView Session